- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance
One-click tool is designed to deliver precision consistently across all imaging modalities.
Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool.
This tool is designed to automate segmentation and measurement of suspicious findings across all imaging modalities, potentially improving workflow and reporting precision. Still, company officials noted, users can maintain full control and modify any automated measurement if they choose.
At left, one-click segmentation and measurement rendered by DL Precise. At right, DL Precise uses vivid color to illustrate segmentation.
Credit: DeepLook
DL Precise uses deterministic algorithms to contour object margins and measure long and short dimension axes, area, and estimated volume. With its single-click activation, it side-steps the complex, time-consuming manual set-up that frequently comes with current semi-automatic segmentation tools.
Not only does DL Precise work with any DICOM image and on all 510(k)-cleared viewers, but its patented technology can also be used universally with mammography, ultrasound, CT, and MRI, and the data captured can be fed directly into structured reports, making image comparisons across modalities easier. It can also be adapted to each viewer interface for easy PACS integration, according to company data.
DeepLook also has plans for future decision-support and diagnostic products based on radiomic data.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
